From the Journals

New PsA questionnaire fails to beat existing early screening methods


 

FROM JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY


AbbVie supported this study with an educational grant. The study was supported by the National Institute for Health Research Leeds Biomedical Research Centre. Some of the authors reported potential conflicts of interest.

SOURCE: Coates L et al. J Eur Acad Dermatol Venereol. 2018 Mar 26. doi: 10.1111/jdv.14971.

Pages

Recommended Reading

Ultrasound study supports deep Koebner mechanism in PsA pathology
MDedge Rheumatology
Arthritis limits physical activity the most in the South
MDedge Rheumatology
FDA approves IL-23 antagonist for plaque psoriasis
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Rheumatology
TB in 2017: Good news and bad news
MDedge Rheumatology
Most PsA patients discontinue initial biologic within 12 months
MDedge Rheumatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Rheumatology
Reassurance for women taking certolizumab during pregnancy
MDedge Rheumatology
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Rheumatology

Related Articles

  • Latest News

    Make a PEST of your psoriasis patients

    KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.